Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
The Future of GLP-1RAs in Obesity Treatment: Expert Perspective
With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.
The future of glucagon-like peptide-1 (GLP-1) receptor agonists in obesity treatment holds significant promise, though current challenges such as supply shortages, cost, and insurance coverage persist. The long-term success of GLP-1 receptor agonists hinges on a multifaceted approach that incudes lifestyle interventions, medication adherence, and addressing weight bias and stigma, according to Michael Crotty, MD, a general practitioner who specializes in obesity medicine and is co-founder of My Best Weight in Dublin, Ireland. He explains in the short video above.
Recent Videos
Related Content
